Browsed by
Tag: Data

Dotmatics Introduces Blueprint to Provide Self-service Data Analysis for Medicinal and Synthetic Chemists

Dotmatics Introduces Blueprint to Provide Self-service Data Analysis for Medicinal and Synthetic Chemists

  • Self-service scientific data visualization and analytics application designed to empower chemists working on small molecule discovery projects

  • Blueprint provides guided wizard-driven analytics for bench scientists to analyze project data, design compounds and make informed decisions, faster

  • Web-based solution fully integrated into existing Dotmatics applications to provide a seamless end-to-end chemistry design workflow

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. The introduction of Blueprint broadens the existing Dotmatics suite for chemistry design workflows, adding to the Company’s comprehensive selection of web-based solutions.

As drug discovery research continues to become increasingly data-driven, the limited availability of specialist data scientists and computational chemists, in addition to the complexity and restrictions of legacy cheminformatics tools, have become a bottleneck for research organizations. There is now a high demand for self-servicing tools, specifically aimed at non-data-specialists, to increase workflow efficiency and staff productivity. Designed to support project scientists with minimal training, Blueprint employs guided wizard-driven analytics to enable users to analyze structure-activity data, design compounds and rapidly make the best-informed decisions with real-time data. The application also facilitates collaboration in-house or with external partners. Blueprint seamlessly integrates into the existing Dotmatics suite of search and experiment capture capabilities which support the full drug discovery cycle, from compound design to analysis. Within a single workflow, scientists can assemble project data across multiple third-party systems; explore molecular data sets; design new molecular series or libraries; and automatically generate experiments in their electronic lab notebook.

Dr Stephen Gallagher, Co-Founder and Chief Executive Officer Dotmatics, commented:Blueprint is a key new component of the Dotmatics solution

Read the rest
Cash Flow Analysis: There Is An Opportunity For Automatic Data Processing To Improve Its Valuation (NASDAQ:ADP)

Cash Flow Analysis: There Is An Opportunity For Automatic Data Processing To Improve Its Valuation (NASDAQ:ADP)

Automatic Data Processing (ADP) was going strong into 2020 and they laid out plans in their February Investor Day of goals to have 5-6% top-line growth given their new product rollouts, large addressable market, and favorable operating environment. Both the business performance and stock price were hit hard by the COVID-19 pandemic. Although FY20 revenue and margins were slightly higher compared to the previous year, the fourth quarter ended 6/30 was rough as revenue declined and margins compressed. To preserve cash, management put share repurchases on hold. These were reasons why the stock price crumbled from ~$180 per share to ~$140 per share before rebounding to where it is currently trading ~$160 per share. This article will explore ADP’s future cash flows and valuation to see if there is coverage for business operations, expansion, share buybacks, and dividends, and how ADP can expand its premium.


ADP had some consistent revenue growth over the last several years. The real outlier was FY20 that was plagued by the pandemic.

Source: Seeking Alpha

The figures outlined in the FY20 Press Release show how the pandemic impacted the fourth quarter (the wavy highlighting was included for emphasis). Bookings were down, retention rate was down, and margins were down. A bright spot is that the business was doing well enough into the second half that they still generated revenue growth.

In February, ADP had its Innovation Day and it laid out its plans for long term of 5-6% per annum. This was to be achieved by continuing to penetrate the addressable market and rolling out products that they spent a bunch of capital on. 2020 was to be the year that these new products were supposed to be scaled and drive incremental revenue. The increase in sales from these products will not be as

Read the rest
Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata

  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time

  • Session: D1T03.3C: Late-Breaking News Session

  • Location: EADV Virtual Meeting. Registration is required to participate:

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious

Read the rest
Here’s what 710 years’ worth of Italian bond market data is showing about central banks ‘crushing rates’

Here’s what 710 years’ worth of Italian bond market data is showing about central banks ‘crushing rates’

The yield on Italian 10-year

and 30-year

debt fell to record lows on Monday.

As this chart from Deutsche Bank shows, the yield on the Italian 10-year is lower than it was even before Italy became a country. Deutsche Bank strategist Jim Reid attached proxies for Italian debt, such as from Naples, to chart pre-1861 data. (There is also a gap in the data series for the 1700s.)

He also charted debt-to-gross-domestic-product, which shows the Italian economy with an all-time low capability to service that debt.

The move on Monday came after the European Central Bank’s chief economist gave an interview suggesting the central bank may take further action. Among the ECB’s actions stimulus so far is the purchase of government debt from countries including Italy, through what’s called the pandemic emergency purchase program.

“Has the ECB permanently suppressed yields and spreads or are there many more twists and turns to this story over the years ahead? I would lean towards the latter but for now Italian politics and their control of the second wave are acting as strengths and not weaknesses,” Reid said.

David Stockman, the former Reagan-era budget director and acerbic critic, looked at the same chart and issued this brief but withering analysis: “when central banks crush rates, politicians bury their governments in debts.”

The current explosion in debt-to-GDP has been because the latter dropped, precipitously. The Italian economy shrank by 18% year-over-year in the second quarter.

Italy also has been issuing more debt. According to Italian bank Intesa Sanpaolo, Italy is forecast to issue a net €177 billion in new debt in 2020, compared with €54 billion in 2019.

Source Article Read the rest

Market Outlook: Forget About Political Noise And Follow The Data

Market Outlook: Forget About Political Noise And Follow The Data

The market has been dancing to the tune of political developments lately. The coronavirus stimulus negotiations are having a material impact on prices in the short term, and investors are clearly worried about the coming elections and what they could mean for the stock market going forward.

Politics is important. As citizens, we should always be mindful of what is going on in the political scenario and we should always try to make well-informed and conscious decisions when the time to vote comes.

As investors, however, we should rather focus on variables with a proven and measurable impact on markets, and this does not include political speculation.

As opposed to trying to predict the future evolution of prices, investors should rather focus on assessing the market environment and adapting to it. The statistical evidence shows that momentum is a pervasive phenomenon in the market, and the momentum indicators are currently bullish for stocks.

Speculation Can Be Hazardous To Your Wealth

It is not that political developments are irrelevant to the stock market, they do matter, and sometimes they matter a lot. However, history shows that trying to make investment decisions based on political considerations tends to backfire more often than not.

Let’s take a look at a few noteworthy examples. On March 6, 2009, the Wall Street Journal published an article on how Obama’s radicalism was killing the stock market. As it turns out, this was a spectacular buying opportunity in retrospect.

ChartData by YCharts

Before Trump won the election in 2016, investment banks were predicting a decline of 10% to 15% in case this happened. During the night when Trump won the election in 2016, the stock market futures were plunging. That same night The New York Times published the following paragraphs by Paul Krugman:

It really does now

Read the rest